At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Cannabidiol suppository intervention 1 (supplement), Cannabidiol suppository intervention 2 (supplement), Cannabidiol suppository intervention 3 (supplement), Non cannabidiol group control (other)
- How long the study runs
- Study runs about 23 months (dates as stated)
- About the drug or intervention
- Cannabidiol suppository intervention 1 — supplement: Cannabidiol suppository dose specific 30mg · Cannabidiol suppository intervention 2 — supplement: Cannabidiol suppository dose specific 50mg · Cannabidiol suppository intervention 3 — supplement: Cannabidiol suppository dose specific 100mg · Non cannabidiol group control — other: Care as usual group
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years to 100 Years
- Who
- All
- Number of participants
- 50
- Started
- 2026-01-16
- Last checked
- 2026-01
Plain English Summary
What is this study?
- • Testing a new treatment for well-being, psychological
- • NA - 50 participants
- • Research aim: To determine how cannabidiol suppositories might reduce sexual pain during intimacy
Who can take part?
- • Ages 18 Years to 100 Years
- • Diagnosed with well-being, psychological
Where?
- • London - School of Social Sciences and Professions
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Research aim: To determine how cannabidiol suppositories might reduce sexual pain during intimacy. Outcomes are also hoped to increase sexual functioning, well-being, and quality of life. Research intention: If cannabidiol suppository intervention reduces sexual pain and increases general well-being, then this research would be repeated on a larger scale, targeting psychosexual services. A brief overview of the intervention: Quantitatively, randomisation of cannabidiol suppositories will be into dose-specific groups. The intervention will be delivered over a period of one month, with follow-up scheduled at 12 weeks. Qualitatively, participants were asked approximately eight open-ended feedback questions throughout the study.
More detail
Sexual pain is a constellation of biopsychosocial disorders which affects men, women and their partners. Cannabidiol is one of approximately 100 cannabinoids found in cannabis, alongside tetrahydrocannabinol. Cannabidiol is non-intoxicating and regarded as a safe product to use. Cannabidiol has many applications, including in sexual health. Two studies have examined cannabidiol suppositories for supporting sexual function and reducing sexual pain. In both studies, outcomes suggested the pain relieving qualities of cannabidiol oil for both men and women. This research aims to establish the effectiveness of varied doses of cannabidiol oil to minimise sexual pain and increase well-being. This research is a preliminary study looking at how cannabidiol suppositories aim to reduce pain and support sexual function, wellbeing and quality of life among those experiencing sexual discomfort or pain during intercourse or masturbation. There will be four groups, where cannabidiol will be randomised to dose-specific groups, approximately 30, 50, and 100mg, under the guidance of a medical practitioner. There will also be a care as usual group. It is hypothesised that: Higher levels of sexual functioning, quality of life and wellbeing with lower levels of sexual pain will be reported among those using cannabidiol suppositories at the follow-up after intervention compared to care as usual group. It is further hypothesised that higher doses of cannabidiol suppositories will have higher levels of sexual pain-reducing outcomes.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 100 Years
- Who can join: All genders
What the study is looking for
- ✓Has previously used cannabidiol in any capacity and has not experienced any allergic reaction
- ✓Is experiencing sexual pain
- ✓There will be an absence of co occurring difficulties
- ✓Has attempted sexual intercourse in the last month
- ✓Age 18 years or older
Who cannot take part
- ✗Has experienced an allergic reaction to cannabidiol in any capacity
- ✗Has not attempted sexual intercourse in the last month
- ✗Has co occurring difficulties
- ✗Aged below 18 years old
- ✗Are not experiencing sexual pain
See the full criteria
Where Is This Study? (1 UK site)
School of Social Sciences and Professions
London N7 8DB, United Kingdom
How to Get in Touch
Anna Kamyk
Sponsor contactCONTACT